摘要
舒尼替尼是一种多靶点的小分子酪氨酸激酶抑制剂,对多种介导肿瘤发生发展的激酶均有抑制作用,目前已用于肾细胞癌、胃肠道间质瘤等多种肿瘤的治疗。神经内分泌瘤是罕见的恶性肿瘤类型,占全部恶性肿瘤的比例不足1%,理论上可发生于整个神经内分泌系统,但多发生于胃、肠、胰腺。该药已被批准用于胰腺神经内分泌瘤的治疗,且收到较好的近远期效果。本文就舒尼替尼治疗神经内分泌瘤的疗效、不良反应和疗效影响因素等方面进行综述,现报道如下。
Sunitinib is a kind of multi targets for small molecule tyrosine kinase inhibitors,for a variety of mediated by the occurrence and development of tumor kinase inhibited,has been used for renal cell carcinoma,gastrointestinal stromal tumors and other neoplasms therapy.Neuroendocrine tumors are rare malignant tumor types,the total proportion of malignant tumors of less than 1%,could theoretically happen on the neuroendocrine system,but often occurs in the stomach,intestine,pancreas.The drug has been approved for the treatment of pancreatic neuroendocrine tumors,and received a better long term outcome.In this paper,sunitinib therapy neuroendocrine tumor of the efficacy,adverse reactions and the effect factors are reviewed,report as follows.
出处
《药品评价》
CAS
2012年第30期44-46,共3页
Drug Evaluation
